• LAST PRICE
    3.3000
  • TODAY'S CHANGE (%)
    Trending Down-0.0700 (-2.0772%)
  • Bid / Lots
    3.2200/ 1
  • Ask / Lots
    3.2900/ 1
  • Open / Previous Close
    3.3100 / 3.3700
  • Day Range
    Low 3.3000
    High 3.4300
  • 52 Week Range
    Low 3.0000
    High 9.3990
  • Volume
    12,615
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.37
TimeVolumeALBT
09:32 ET10733.31
09:39 ET1003.43
09:48 ET1743.32
10:00 ET2803.35
10:18 ET3503.3513
10:20 ET2003.3985
10:31 ET13573.3502
10:49 ET17903.3201
10:51 ET11593.32
11:07 ET2003.3118
11:30 ET7103.3796
11:38 ET3003.37
12:03 ET3243.3001
12:21 ET1003.33
12:24 ET20843.3
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALBT
Avalon Globocare Corp
33.7M
-25.6x
---
United StatesEVGN
Evogene Ltd
30.9M
-1.0x
---
United StatesMRKR
Marker Therapeutics Inc
29.5M
-6.9x
---
United StatesIMMX
Immix Biopharma Inc
33.6M
-0.7x
---
United StatesBTTX
Better Therapeutics Inc
34.0M
-0.5x
---
United StatesTFFP
TFF Pharmaceuticals Inc
34.4M
-0.7x
---
As of 2023-01-27

Company Information

Avalon GloboCare Corp. is a clinical-stage, vertically integrated, CellTech bio-developer. The Company provides immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics, and therapeutics. It operates through two segments: real property and medical related consulting services. Its major clinical programs include AVA-001, AVA-011 and FLASH-CAR, ACTEX, and AVA-Trap. It also provides strategic advisory and outsourcing services to facilitate and enhance its client's growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its services include research studies, executive education, daily online executive briefings, expert advisory services, and consulting and management services.

Contact Information

Headquarters
4400 ROUTE 9, SUITE 3100FREEHOLD, NJ, United States 07728
Phone
732-780-4400
Fax
732-780-5600

Executives

Chairman of the Board of Directors
Wenzhao Lu
President, Chief Executive Officer, Director
David Jin
Chief Financial Officer
Luisa Ingargiola
Chief Operating Officer, Director
Sarah Cox
Director
Lourdes Felix

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$33.7M
Revenue (TTM)
$1.2M
Shares Outstanding
10.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.60
EPS
$-0.13
Book Value
$0.03
P/E Ratio
-25.6x
Price/Sales (TTM)
27.2
Price/Cash Flow (TTM)
---
Operating Margin
-711.48%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.